Ahmedabad, India, and Planegg-Martinsried, Germany, October 13, 2026
Zydus Lifesciences Limited and Formycon AG have announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for FYB206, their proposed biosimilar to Keytruda® (pembrolizumab), for review. The companies stated that, to their knowledge, this is the first publicly announced FDA acceptance of a filing for a proposed Keytruda biosimilar. Submitted during the third quarter of 2026, the application marks an important regulatory milestone in the development of a potential alternative to one of the world’s leading cancer medicines. Under the companies’ expected regulatory timeline, an FDA decision could arrive in the third quarter of 2027, although the review outcome and timing remain subject to the agency’s assessment. The regulatory dossier has also been submitted to Health Canada. If approved, FYB206 could expand the range of pembrolizumab treatment options available in North America, subject to regulatory requirements and resolution of applicable intellectual property matters. FYB206 remains investigational and is not approved for use in any country.
FDA Accepts FYB206 Application for Regulatory Review
The FDA’s acceptance of the BLA allows the agency to begin its substantive review of FYB206. Under the Biosimilar User Fee Amendments framework, the FDA aims to complete review within the applicable target timeline, which the companies estimate could lead to a decision in the third quarter of 2027. Acceptance for review does not mean that the product has been approved or that its biosimilarity has been established. Regulatory authorities must assess the submitted evidence and determine whether the proposed medicine meets applicable standards for quality, safety and efficacy. FYB206 is being developed as a proposed biosimilar to pembrolizumab, a monoclonal antibody that blocks the programmed death-1 (PD-1) immune checkpoint receptor. By inhibiting PD-1 signaling, pembrolizumab can help restore antitumor immune responses and is used in the treatment of multiple cancer types. The application represents a significant step for the development program, as the companies work toward potential entry into the U.S. and Canadian markets. The filing has also attracted attention because Keytruda remains one of the world’s best-selling biologic medicines, with substantial global demand across oncology indications.
Development Pathway Avoided Comparative Phase 3 Trial
Formycon stated that FYB206 was developed without a comparative Phase 3 efficacy trial, following discussions with the FDA in early 2025. Biosimilar development generally relies on a totality-of-evidence approach, including detailed analytical comparisons, functional characterization and other appropriate evidence to demonstrate that a proposed product is highly similar to its reference medicine and has no clinically meaningful differences in safety and effectiveness. The development pathway agreed with the FDA allowed Formycon to advance FYB206 without conducting a comparative Phase 3 efficacy study. This approach may reduce development time and costs compared with programs that include such trials, while still requiring the sponsor to meet the regulator’s scientific and quality standards. The absence of a comparative Phase 3 efficacy trial does not mean that the product has already demonstrated biosimilarity or received regulatory approval. The FDA will assess the complete application before determining whether FYB206 can be authorized. The companies have described the filing as an important milestone for their oncology biosimilar strategy, but further regulatory review remains necessary before any commercial launch can take place.
Advertisement
Zydus and Formycon Prepare for North American Commercialization
The companies entered into an exclusive licensing and supply agreement for FYB206 in the United States and Canada in December 2025. Under the agreement, Formycon is responsible for completing development, preparing and filing regulatory dossiers, and supplying the product, while Zydus holds exclusive commercialization rights in both markets. The FDA’s acceptance of the BLA also triggers a regulatory milestone payment to Formycon under the agreement. Zydus brings experience in the North American pharmaceutical market and intends to use its oncology commercial capabilities to support the potential launch, subject to approval and resolution of relevant intellectual property issues. Formycon retains global rights to FYB206 and participates in the gross profits generated by its commercialization partners. The proposed biosimilar could be commercially significant given the scale of the pembrolizumab market: the companies reported that global sales of Keytruda, including its subcutaneous formulation Keytruda Qlex, reached US$31.7 billion in 2025. However, market opportunity does not guarantee approval, market access or commercial success. The regulatory outcome, competition, pricing and intellectual property considerations will influence any future launch.
The FDA’s acceptance of FYB206 for review marks an important development in the oncology biosimilar sector. Through their collaboration, Zydus and Formycon aim to expand potential access to pembrolizumab-based cancer treatment in North America. The next major milestone will be the FDA’s decision, which will determine whether FYB206 can proceed toward commercialization.
Source: Zydus Lifesciences, Formycon press release
